

01-24-03

1653



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(MBHB Case No. 02-262)

In re Application of:

Sham-Yuen Chan

Serial No.: 09/441,654

Filed: November 12, 1999

For: Method of Producing
Glycosylated Bikunin

)
)
)
) Group Art Unit: 1653
)
) Examiner: G. Bugaisky
)
)
)
)

RECEIVED
JAN 28 2003
TECH CENTER 1600/2900

Assistant Commissioner for Patents
Washington, D.C. 20231

TRANSMITTAL LETTER

Dear Sir:

In regard to the above-identified patent application:

1. We are transmitting herewith the attached:
 - a. Transmittal Letter, in duplicate;
 - b. Response to Office Action, mailed October 23, 2003; and
 - c. Return Receipt Postcard.
2. With respect to additional fees:

 x A. No additional fee is required.

 B. Attached is a check in the amount of \$.
3. Please charge any additional fees or credit overpayment to Deposit Account No. 13-2490.
4. CERTIFICATE OF MAILING UNDER 37 CFR § 1.10: The undersigned hereby certifies that this Transmittal Letter and the document(s) as described in paragraph 1 hereinabove, are being deposited with the United States Postal Service with sufficient postage as Express Mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on this 22nd day of January, 2002.
EXPRESS MAIL NO.: EV 214232773 US

Date: January 22, 2003By: Aaron F. Barkoff

Aaron F. Barkoff
Reg. No. P52,591



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Attorney Docket No. 02-262)

#18
Amdt/CWg
PATENT
2/3/03

In re the Application of:)
)
Chan et al.)
)
Application No.: 09/441,654)
)
Filing Date: November 12, 1999)
)
For: Method of Producing)
Glycosylated Bikunin)
)

Examiner: Bugaisky, Gabriele E.

Art Unit: 1653

Confirmation No.: 4743

RECEIVED
JAN 28 2003
TECH CENTER 1600/2800

RESPONSE TO THE OFFICE ACTION MAILED OCTOBER 23, 2002

Commissioner for Patents
Washington, D.C. 20231

Sir:

In Response to the Office Action mailed October 23, 2002, the applicants request that the Patent Office consider the following amendments and remarks.

Amendments

In the Specification:

On page 2, please replace the first paragraph with the following paragraph:

Placental bikunin, a novel human serine protease inhibitor containing two Kunitz-like domains, has been cloned and expressed (Delaria et al., J. Biol. Chem. 272(18): 12209-12214, 1997). Characterization studies showed that truncated placental bikunin is a potent inhibitor of kallikrein and plasmin. The sequence of truncated placental bikunin is shown in Figure 2. The protease inhibitory function of bikunin suggests that placental bikunin has important therapeutic application for the treatment of a variety of disorders including prevention of disseminated